Jing Liang, Founder and Managing Partner at Applehelix Venture Studio, shared an update from Drew Moghanaki, Chief of Thoracic Oncology at David Geffen School of Medicine at UCLA, on X, adding:
“72% of lung cancers are diagnosed only after they have spread to lymph nodes or have metastasized, where 5-year survival rates are much lower. Yet we still have philosophical debates whether we should screen for cancers earlier. You basically have the ‘sensible medicine’ camp that says if it doesn’t bother you, don’t worry about it. And that cancer screening causes more harm.
On the cancer screening causes more harm ‘assertion’, I have yet to see rigorous quantification of this phenomenon. Every single argument uses theoretical conjecture. Even if it is true, the logical solution is not ‘lets not screen’ but figure out how to minimize potential side effects of screening.”
Quoting Drew Moghanaki:
“It remains shocking that lung cancer kills 2,000,000 people a year around the world, yet access to early-detection LDCT screening remains limited and mired in ambivalence. Thanks to the BMS Foundation and the stalwart leadership of Catharine Grimes, we will tackle this topic head-on with international experts at the upcoming WCLC conference in Seoul.
Register here if you’d like to learn more about how we are tackling the needed policy changes at the national level across multiple continents to help more people survive this dreaded disease and live their lives without dying from lung cancer first.”
You can find this interesting:
INTEGRAL-Risk May Refine Lung Cancer Screening Eligibility
